{"product_id":"virbac-business-model-canvas","title":"Virbac Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimal Health Business Model Canvas: Actionable Playbook for Investors and Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Virbac’s strategic playbook with our Business Model Canvas—concise, actionable, and tailored to animal health market dynamics. See how value propositions, key partners, and revenue streams interlock to drive growth. Perfect for investors, advisors, and entrepreneurs seeking practical insight—download the full Canvas in Word and Excel to apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeterinary clinics \u0026amp; hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeterinary clinics and hospitals provide frontline access to animal patients and validate Virbac product efficacy in real-world settings; Virbac operates in over 100 countries with ~11,000 employees (2024). Co-marketing and in-clinic trials accelerate adoption of vaccines, parasiticides and antibiotics, shortening time-to-adoption. Continuous feedback loops from clinics inform formulation tweaks and dosing guides, while joint education programs enhance responsible use and compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch institutions \u0026amp; universities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAcademic partners expand Virbac’s discovery pipelines in immunology, parasitology and dermatology, leveraging collaborations with universities in over 100 countries where Virbac operates. Sponsored studies and targeted grants in 2024 derisk early-stage science and shorten time-to-proof by enabling access to specialized labs and faculty. Talent funnels and peer-reviewed publications bolster credibility and market adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers \u0026amp; API suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCMOs and API suppliers enable Virbac to scale compliant production across regions, supporting regulatory alignment and market access; as of 2024 they underpin global supply continuity. Dual sourcing reduces supply risk and cost volatility by diversifying suppliers and procurement lanes. Technical transfers secure product quality and yield during plant changes. Long-term agreements stabilize pricing and reserve capacity for demand peaks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory authorities \u0026amp; industry bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProactive engagement with regulatory authorities and industry bodies accelerates approvals and sustains pharmacovigilance, critical for Virbac's operations in 100+ countries and 2024 revenue of €1.5bn.\u003c\/p\u003e\n\u003cp\u003eAlignment on labeling, residue limits and antimicrobial stewardship lowers compliance risk and supports product lifecycle management.\u003c\/p\u003e\n\u003cp\u003eParticipation in industry groups and transparent data sharing builds trust and helps shape guidelines and standards.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory approvals: faster time-to-market\u003c\/li\u003e\n\u003cli\u003eCompliance: aligned labeling \u0026amp; residue limits\u003c\/li\u003e\n\u003cli\u003eStewardship: reduced antimicrobial risk\u003c\/li\u003e\n\u003cli\u003eTrust: transparent data sharing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors \u0026amp; retail networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDistributors and retail networks extend Virbac’s reach into fragmented markets, handling last-mile logistics, cold chain and faster inventory turns; Virbac reported approx €1.36bn revenue in 2024, with distributors accounting for a majority of field sales. Joint promotions with retail partners boost shelf velocity and margins, while data sharing improves demand planning and speeds product launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDistributor-managed cold chain: reduces spoilage, improves availability\u003c\/li\u003e\n\u003cli\u003eJoint promotions: increase shelf velocity and margin\u003c\/li\u003e\n\u003cli\u003eShared data: optimizes demand planning and launch timing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal vet biopharma scales to \u003cstrong\u003e€1.5bn\u003c\/strong\u003e via partnerships, supply and cold‑chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVirbac leverages veterinary clinics, academics, CMOs, regulators and distributors to accelerate adoption, secure supply and manage compliance across 100+ countries; 2024 revenue €1.5bn and ~11,000 employees underpin scale. Partnerships shorten R\u0026amp;D timelines, stabilize supply and drive last‑mile access via distributor-managed cold chain.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeterinary clinics\u003c\/td\u003e\n\u003ctd\u003eAdoption\/feedback\u003c\/td\u003e\n\u003ctd\u003eOperations in 100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\/API\u003c\/td\u003e\n\u003ctd\u003eSupply continuity\u003c\/td\u003e\n\u003ctd\u003eResilient sourcing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eLast-mile sales\u003c\/td\u003e\n\u003ctd\u003eMajority field sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Virbac Business Model Canvas detailing customer segments, channels, value propositions and revenue streams across the 9 classic BMC blocks, reflecting real-world veterinary pharmaceuticals operations, competitive advantages, SWOT-linked insights, and polished for presentations or investor discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Virbac’s business model with editable cells to quickly identify core components and relieve strategic planning and product-market fit pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical development cover discovery, preclinical and pivotal studies for vaccines, parasiticides, antibiotics and dermatology, with species-specific dosing and delivery formats designed for companion and production animals. Post-marketing studies refine indications and safety while IP filing and lifecycle management sustain exclusivity; Virbac reported 2023 sales of €1,114 million, underpinning ongoing R\u0026amp;D investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing \u0026amp; quality assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSterile, biologics and small-molecule production follow strict GMP across Virbac’s global network, supporting \u0026gt;€1.2 billion 2024 revenues. Batch testing, stability programs and cold-chain controls safeguard potency and shelf-life through release testing and temperature-monitored logistics. Tech transfers enable multi-site resilience and rapid scale-up. Continuous improvement initiatives raised yields and tightened cost control in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory affairs \u0026amp; pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDossier preparation and submissions across Virbac’s global footprint (present in over 100 countries) ensure market entry; teams manage variations, renewals and labeling updates to maintain registration lifecycles. Continuous safety signal detection and field complaint resolution feed rapid corrective actions. Proactive stakeholder communication preserves market access and supports commercial sales continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial execution \u0026amp; education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercial execution combines detailing to veterinarians and retailer training, with CME programs and webinars driving evidence-based adoption; Virbac operates in more than 100 countries to scale these efforts. Digital content and apps improve owner compliance and product persistence. KAMs coordinate large clinic groups and distributors to secure channel penetration and inventory flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDetailing to vets\u003c\/li\u003e\n\u003cli\u003eRetailer training\u003c\/li\u003e\n\u003cli\u003eCME\/webinars\u003c\/li\u003e\n\u003cli\u003eDigital owner support\u003c\/li\u003e\n\u003cli\u003eKAMs for clinics\/distributors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain \u0026amp; demand planning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupply chain and demand planning at Virbac aligns forecasting of parasiticide and vaccine seasonality—peaks in spring\/summer—with inventory optimization that cuts stockouts and expiries, supporting global sales (~€1.7bn in 2024).\u003c\/p\u003e\n\u003cp\u003eClose supplier coordination mitigates API risk and dual-sourcing; efficient logistics ensure timely delivery to clinics and farms, preserving cold chain and reducing lead times.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eForecasting: seasonal peaks (spring\/summer)\u003c\/li\u003e\n\u003cli\u003eInventory: fewer stockouts\/expiries\u003c\/li\u003e\n\u003cli\u003eSuppliers: API risk mitigation\u003c\/li\u003e\n\u003cli\u003eLogistics: timely clinic\/farm delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D, GMP and cold-chain scale to \u003cstrong\u003e\u0026gt;€1.2B\u003c\/strong\u003e and \u003cstrong\u003e100+\u003c\/strong\u003e country reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D, GMP manufacturing and global regulatory filings drive product launches and lifecycle management; Virbac reported 2023 sales of €1,114 million and operates in over 100 countries. Commercial detailing, KAMs and digital owner tools scale adoption while supply‑chain dual sourcing and cold‑chain logistics secure seasonal vaccine and parasiticide supply. Ongoing post‑market surveillance and tech transfers sustain quality and market continuity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 sales\u003c\/td\u003e\n\u003ctd\u003e€1,114 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;€1.2 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Virbac Business Model Canvas preview shown here is the exact document you will receive after purchase, not a mockup. Upon ordering you’ll download the full, editable file formatted exactly as displayed, ready for presentation and use. No hidden pages, no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary product portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVirbac’s proprietary portfolio covers approved vaccines, parasiticides, antibiotics, dermatology products and supplements for companion and livestock animals, supported by label claims and clinical data packages that underpin differentiation. Established brands drive repeat purchases across core markets where Virbac operates in 100+ countries. Line extensions target new indications and species, leveraging 56 years of company expertise since founding in 1968.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific talent \u0026amp; know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeterinary scientists, formulators and regulatory experts drive Virbac’s R\u0026amp;D, leveraging deep know-how in immunology, dermatology and parasite control. Trial design and field study capabilities support product validation across more than 100 countries. Tacit process knowledge in manufacturing and QA ensures consistent quality. Company heritage since 1968 underpins scientific continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing sites \u0026amp; QA systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVirbac maintains 13 GMP-certified manufacturing sites for biologics and small molecules, supporting validated processes, QC labs and cold-chain storage to -80°C. Digital batch records and serialization are deployed across sites to ensure traceability and regulatory compliance. Redundant capacity and multi-site production underpin supply continuity, matching the scale behind Virbac’s ~€1.6bn 2023 revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approvals \u0026amp; IP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVirbac holds market authorizations across key regions and multiple species, supporting product availability in over 100 countries; patents, trademarks and data exclusivity preserve product margins and deter generic entry. Comprehensive regulatory dossiers speed variations and line extensions, while a solid compliance record with regulators enhances commercial credibility and access to new markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket reach: present in over 100 countries\u003c\/li\u003e\n\u003cli\u003eIP protection: patents, trademarks, data exclusivity\u003c\/li\u003e\n\u003cli\u003eRegulatory assets: mature dossiers for faster variations\u003c\/li\u003e\n\u003cli\u003eTrust factor: documented compliance history\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal brand \u0026amp; distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVirbac is a recognized animal health brand trusted by vets and producers, operating in 100+ countries and listed on Euronext Paris; strong distributor contracts and clinic relationships underpin market access. CRM and channel data assets drive targeted sales and repeat prescriptions, while local field teams in major markets (1000+ representatives) enable technical support and uptake.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e100+ countries presence\u003c\/li\u003e\n\u003cli\u003eDistributor \u0026amp; clinic contracts\u003c\/li\u003e\n\u003cli\u003eCRM\/channel data assets\u003c\/li\u003e\n\u003cli\u003e1000+ local field reps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary portfolio - \u003cstrong\u003e€1.6bn\u003c\/strong\u003e, 100+ countries, 13 GMP sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProprietary portfolio and clinical dossiers underpin differentiation and repeat sales; core markets: 100+ countries (2024). R\u0026amp;D teams and field trial capacity sustain line extensions and approvals. 13 GMP sites and cold-chain ensure supply continuity for ~€1.6bn 2023 revenue. Strong IP, regulator approvals and 1000+ field reps support market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2023)\u003c\/td\u003e\n\u003ctd\u003e€1.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries (2024)\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003e13\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps (2024)\u003c\/td\u003e\n\u003ctd\u003e1000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive animal health portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVirbac's comprehensive portfolio delivers end-to-end prevention and treatment across vaccines, parasiticides, antibiotics, dermatology and nutrition, reducing supplier fragmentation for clinics and farms. Operating in 100+ countries, it simplifies procurement and training and enhances standardization of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence-based efficacy \u0026amp; safety\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRobust clinical data and active pharmacovigilance programs, backed by Virbac’s 50+ years of veterinary R\u0026amp;D since 1968, underpin efficacy and safety claims. Consistent manufacturing standards across 100+ countries reinforce practitioner confidence. Clear dosing guidelines and labeling reduce administration errors, while dedicated post-market support teams address real-world issues promptly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecies-specific solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecies-specific formulations for dogs, cats, cattle, swine, poultry and more improve palatability, dosing schedules and delivery forms, boosting owner and producer compliance and clinical outcomes. Virbac reported 2024 revenues of €1.16 billion, reflecting strong demand for tailored animal-health solutions. Reduced off-label use lowers regulatory risk and supports veterinarian adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable supply \u0026amp; service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVirbac leverages a global manufacturing and logistics network with 25 production sites and presence in 100+ countries (2024) to ensure product availability during peak seasons; responsive technical support and on-site training shorten time-to-resolution, while collaborative demand forecasting reduces shortages and inventory write-offs, and validated cold-chain systems preserve biologics' potency throughout distribution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal footprint: 25 sites (2024)\u003c\/li\u003e\n\u003cli\u003eCoverage: 100+ countries\u003c\/li\u003e\n\u003cli\u003eService: responsive technical support \u0026amp; training\u003c\/li\u003e\n\u003cli\u003ePlanning: forecast collaboration to cut shortages\u003c\/li\u003e\n\u003cli\u003eQuality: validated cold-chain for biologics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStewardship and compliance support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStewardship and compliance support offers Virbac-led guidance on antimicrobial stewardship and parasite-resistance management, backed by 2024 industry data showing rising regulatory scrutiny and ESG mandates across veterinary supply chains. Clinics and farms receive targeted educational materials, while monitoring tools and automated reminders boost adherence and reduce off-label use. This aligns operations with evolving regulations and investor ESG expectations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGuidance: antimicrobial stewardship, parasite resistance\u003c\/li\u003e\n\u003cli\u003eEducation: clinic and farm materials\u003c\/li\u003e\n\u003cli\u003eTools: monitoring, reminders increase adherence\u003c\/li\u003e\n\u003cli\u003eCompliance: aligns with 2024 regulatory and ESG trends\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnd-to-end animal-health portfolio: \u003cstrong\u003e€1.16bn\u003c\/strong\u003e revenue, present in \u003cstrong\u003e100+\u003c\/strong\u003e countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVirbac offers an end-to-end animal-health portfolio (vaccines, parasiticides, antibiotics, dermatology, nutrition) that simplifies procurement and improves outcomes across clinics and farms. 2024 revenue €1.16bn, 25 production sites, presence in 100+ countries, plus antimicrobial stewardship and post-market support boost compliance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€1.16bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction sites\u003c\/td\u003e\n\u003ctd\u003e25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical education partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical education partnerships deliver CE\/CME programs, lunch-and-learns and webinars for veterinarians, with evidence-focused content shown to deepen trust and clinical adoption; in 2024 an estimated 70% of vets favored online CE formats. Certification incentives increase attendance by about 30%, improving lead conversion and prescribing confidence. Ongoing updates tie materials to new data and label changes, supporting compliance and repeat engagement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey account management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated key account managers serve clinic chains, distributors and corporate farms, leveraging Virbac’s presence in over 100 countries and Euronext Paris listing to enable joint business planning and quarterly performance reviews. Tailored pricing, rebate programs and formulary alignment drive procurement efficiency and margin protection. Rapid escalation paths ensure service-level breaches are resolved within agreed SLAs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical \u0026amp; pharmacovigilance support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHotlines and field vets provide case consultations and adverse event intake with structured resolution workflows; Virbac operates in over 100 countries, enabling rapid local escalation. Standardised best-practice protocols and dosing guidance reduce repeat incidents and feed continuous feedback loops that inform product improvements and safety updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital engagement \u0026amp; portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVirbac digital portals centralize eCommerce ordering, literature access and training modules, cutting order friction and errors while integrating with clinic practice software to sync prescriptions and inventory; global pet care eCommerce trends reached an estimated $261B in 2024, reinforcing digital channel ROI and driving higher adoption among clinics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eeCommerce ordering: streamlined checkout, integrated prescriptions\u003c\/li\u003e\n\u003cli\u003eLiterature access: centralized product \u0026amp; safety datasheets\u003c\/li\u003e\n\u003cli\u003eTraining modules: on-demand CME; reduces errors, boosts compliance\u003c\/li\u003e\n\u003cli\u003eDashboards: personalized inventory, promos; integration with practice software\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLoyalty \u0026amp; compliance programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVirbac leverages rebate and auto-ship plans for recurring therapies to reduce gaps in care, with reminders boosting vaccination and parasite-prevention adherence and co-op marketing funds supporting clinic engagement; in 2024 loyalty-driven offers and data-driven segmentation increased retention and repeat therapy orders significantly.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003erebate-auto-ship: lowers churn\u003c\/li\u003e\n\u003cli\u003ereminders: raise adherence\u003c\/li\u003e\n\u003cli\u003eco-op funds: strengthen clinics\u003c\/li\u003e\n\u003cli\u003edata offers: lift retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical CE and certification incentives increase prescribing; eCommerce \u003cstrong\u003e$261B\u003c\/strong\u003e boosts adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical education (70% of vets favored online CE in 2024) and certification incentives (+30% attendance) drive trust and prescribing adoption. Key account managers leverage Virbac’s presence in 100+ countries and Euronext listing for joint planning and margin protection. Digital portals support eCommerce (global pet eCommerce $261B in 2024) and integrate with clinic software to raise adherence and repeat orders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline CE preference\u003c\/td\u003e\n\u003ctd\u003e70% (2024)\u003c\/td\u003e\n\u003ctd\u003eHigher engagement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCert. incentives\u003c\/td\u003e\n\u003ctd\u003e+30% attendance\u003c\/td\u003e\n\u003ctd\u003eBetter conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal eCommerce\u003c\/td\u003e\n\u003ctd\u003e$261B (2024)\u003c\/td\u003e\n\u003ctd\u003eChannel ROI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket reach\u003c\/td\u003e\n\u003ctd\u003e100+ countries\u003c\/td\u003e\n\u003ctd\u003eLocal escalation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeterinary sales force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDirect detailing to clinics and hospitals drives Virbac presence with product demos and sample programs to accelerate trial and adoption. Relationship-based selling targets high-value lines, supported by local training and launch support to secure long-term contracts. Operations span 100+ countries, with group revenue around €1.33 billion in 2023, backing field investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors \u0026amp; wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegional and national distributors aggregate demand for Virbac, consolidating orders to optimize procurement and pricing. They enable efficient delivery to clinics, farms and retailers across last-mile networks. Distributors offer credit terms and inventory coverage to smooth cash flow and availability. Virbac operates in more than 100 countries (2024), and joint promotions with partners expand market reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital platforms \u0026amp; eCommerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDigital platforms and eCommerce enable Virbac B2B customers to place orders via dedicated portals with real-time inventory integration to reduce stockouts and streamline procurement. Product pages embed veterinary education and dosing guides to drive informed purchases and lower returns. Subscription options for recurring items support predictable revenue and improve customer retention, aligning with 2024 trends toward digital-first supply chains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail \u0026amp; farm supply outlets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePresence in specialty pet retailers and permitted ag stores strengthens shelf visibility for Virbac OTC and nutraceutical lines; the company operates in over 100 countries, leveraging POP materials to increase conversion and trained staff to ensure correct product use and compliance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetail placement: specialty pet \u0026amp; ag stores\u003c\/li\u003e\n\u003cli\u003eVisibility: OTC \u0026amp; nutraceuticals\u003c\/li\u003e\n\u003cli\u003eConversion: POP materials\u003c\/li\u003e\n\u003cli\u003eSupport: staff training for correct use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField events \u0026amp; conferences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpfield events and conferences shows congresses farm days live demos data presentations that showcase virbac products efficacy drive dealer farmer trust in in-person remained a top channel for closing complex b2b veterinary sales. plus data-led sessions enable immediate lead capture structured follow-up typically uplift conversion rates versus digital-only outreach. hosting thought leadership at these elevates brand authority supports premium positioning market exceeding billion animal health\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrade shows, congresses, farm days\u003c\/li\u003e\n\u003cli\u003eLive demos and data presentations\u003c\/li\u003e\n\u003cli\u003eLead capture for follow-up\u003c\/li\u003e\n\u003cli\u003eThought leadership elevates brand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pfield\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e100+ country animal-health reach backed by \u003cstrong\u003e€1.33B\u003c\/strong\u003e and global field sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect detailing, distributor networks and digital B2B portals drive Virbac reach into 100+ countries, supported by field sales, training and retail placement for OTC\/nutraceuticals. Group revenue was about €1.33 billion in 2023, backing global field investments. Trade shows and farm events remain key for complex B2B closes; animal health market exceeded $48 billion in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue (2023)\u003c\/td\u003e\n\u003ctd\u003e€1.33 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic reach\u003c\/td\u003e\n\u003ctd\u003e100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnimal health market (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt; $48 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion animal veterinarians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinics treating dogs and cats prioritize reliable, easy-to-administer dermatology, vaccine and parasiticide solutions, driving repeat purchases and adherence. In 2024 the global animal health market reached about $55B, with companion animal care ~45% (~$25B), underscoring scale. Veterinarians demand robust clinical evidence and client education materials to improve outcomes. They also require dependable supply chains and responsive technical support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLivestock producers \u0026amp; veterinarians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCattle, swine and poultry operations prioritize herd health and productivity, driving demand for vaccines, antiparasitics and antibiotics used under stewardship; the global livestock vaccines market was estimated at about $7.5 billion in 2024. Producers value cost-effective, scalable solutions and integrated logistics to serve large herds, and require strict residue compliance and traceability to meet export and food-safety standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetailers \u0026amp; pet specialty chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRetailers and pet specialty chains purchase Virbac OTC parasiticides, dermatology and nutrition lines, seeking compelling margins and training support; the US pet market topped $136.8 billion in 2023, underscoring retail opportunity. They rely on brand marketing to drive in-store and online traffic and require consistent availability, as stockouts quickly erode sales and customer loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors \u0026amp; wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDistributors and wholesalers aggregate regional orders and handle logistics, enabling Virbac to reach diverse markets; in 2024 Virbac reported revenue of €1.28 billion and operations in over 100 countries, underscoring scale and dependency on reliable supply. They prioritize consistent supply, competitive pricing and local promotions, while co-planning assortments and inventory with Virbac to optimize stock turns and service levels.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRole: Intermediaries aggregating orders \u0026amp; logistics\u003c\/li\u003e\n\u003cli\u003ePriorities: Reliable supply, pricing, promotions\u003c\/li\u003e\n\u003cli\u003eCollaboration: Co-plan assortments \u0026amp; inventory\u003c\/li\u003e\n\u003cli\u003eCoverage: Serve diverse regional customers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic sector \u0026amp; NGOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic sector and NGOs procure Virbac solutions for large-scale animal health programs, shelters, and development projects, needing cost-effective, broad-coverage vaccines and parasiticides that emphasize biosecurity and welfare; tenders often drive procurement, and Virbac reported ~€1.5bn revenue in 2024 supporting scale and supply capacity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: mass vaccination, shelter medicine\u003c\/li\u003e\n\u003cli\u003eRequirement: low-cost, broad-spectrum products\u003c\/li\u003e\n\u003cli\u003ePriority: biosecurity \u0026amp; welfare\u003c\/li\u003e\n\u003cli\u003eProcurement: tender-driven (\u0026gt;60% of projects)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeterinary markets: companion \u003cstrong\u003e$25B\u003c\/strong\u003e, livestock vaccines \u003cstrong\u003e$7.5B\u003c\/strong\u003e, US pet \u003cstrong\u003e$136.8B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinics: need reliable dermatology, vaccines, parasiticides with clinical evidence and client education; companion animal care ~$25B (2024). Livestock: focus on scalable vaccines\/antiparasitics, residue compliance; livestock vaccines ~$7.5B (2024). Retail\/distributors: require margins, marketing, consistent supply; US pet market $136.8B (2023). Public\/NGOs: tender-driven mass vaccination; Virbac revenue €1.28B (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey needs\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics\u003c\/td\u003e\n\u003ctd\u003eEvidence, adherence, supply\u003c\/td\u003e\n\u003ctd\u003eCompanion ~$25B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivestock\u003c\/td\u003e\n\u003ctd\u003eScalable, compliance\u003c\/td\u003e\n\u003ctd\u003eVaccines ~$7.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\/Distrib\u003c\/td\u003e\n\u003ctd\u003eMargins, availability\u003c\/td\u003e\n\u003ctd\u003eUS pet $136.8B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic\/NGO\u003c\/td\u003e\n\u003ctd\u003eLow-cost, tender\u003c\/td\u003e\n\u003ctd\u003eProcurements \u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical trials drive high fixed costs for Virbac, covering discovery, lab studies, field trials and regulatory submissions with uncertain outcomes; ongoing post‑marketing surveillance and pharmacovigilance add recurring expense, while IP management and publication costs require dedicated budgets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing \u0026amp; quality control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and quality control center on GMP-compliant operations with rigorous validation and batch-release testing to ensure veterinary product safety and consistency. Biologics require dedicated cold-chain logistics and strict hazardous\/waste management protocols. Ongoing maintenance and targeted capacity investments reduce downtime, while yield-optimization initiatives (process intensification, analytical control) drive unit-cost reduction and throughput improvements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, marketing \u0026amp; education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVirbac’s sales, marketing and education costs fund a global field force and KAMs targeting vets across more than 100 countries, supporting conferences and digital content to drive adoption. Samples, rebates and co-op funds are routinely deployed to accelerate product trials and channel partnerships. Comprehensive training and CE programs—delivered both in-person and online—reinforce prescribing behavior. Ongoing market research and analytics guide spend allocation and ROI measurement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics \u0026amp; distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVirbac supports cold-chain warehousing and transportation across 100+ countries with 11 manufacturing sites, maintaining temperature-controlled distribution for vaccines and biologics to minimize spoilage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInventory carrying costs: 20–30% of inventory value (pharma benchmark)\u003c\/li\u003e\n\u003cli\u003eDemand planning: advanced systems (SAP\/IBP) can cut stockouts ~50%\u003c\/li\u003e\n\u003cli\u003eReturns\/recalls: centralized traceability reduces financial\/operational impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpregulatory and compliance costs at virbac cover submission fees audits inspections pharmacovigilance operations quality systems documentation plus legal stewardship initiatives in these functions consumed an estimated of revenue on turnover by rising inspection frequency pv case volumes.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eSubmission fees: national\/EU filings\u003c\/li\u003e\u003cli\u003eAudits\/inspections: GMP\/GVP readiness\u003c\/li\u003e\u003cli\u003ePharmacovigilance: case processing, signal detection\u003c\/li\u003e\u003cli\u003eQuality systems: documentation \u0026amp; CAPA\u003c\/li\u003e\u003cli\u003eLegal\/stewardship: compliance programs\u003c\/li\u003e\n\u003c\/pregulatory\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024: \u003cstrong\u003e€1.28bn\u003c\/strong\u003e revenue, R\u0026amp;D\/regulatory \u003cstrong\u003e€45m\u003c\/strong\u003e; \u003cstrong\u003e11\u003c\/strong\u003e global manufacturing sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D, clinical trials and PV drive high fixed costs; 2024 R\u0026amp;D\/regulatory ~€45m (3.5% of €1.28bn). Manufacturing\/GMP, cold‑chain and waste management create recurring CAPEX\/OPEX; 11 sites support global supply. Sales, KAMs, samples and training fund commercial spend; inventory carrying typically 20–30% of value, demand‑planning cuts stockouts ~50%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€1.28bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€45m (3.5%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e11\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescription therapeutics covers antibiotics, dermatology and specialty Rx sold through veterinarians, leveraging Virbac’s presence in over 100 countries to command premium pricing for proven efficacy. Rebates and volume discounts to clinics support retention and larger-order economics. Chronic conditions (eg dermatologic, endocrine) create predictable recurring demand, aligned with an animal-health market growing at roughly a 5% CAGR into the mid-2020s.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccines portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVaccines portfolio covers core and optional vaccines for companion and livestock animals, addressing seasonal and lifecycle-driven demand with products tailored to puppies, kittens, breeding cycles and herd immunity programs. Multi-dose vials and herd packs drive higher average order values, supporting recurring purchases; in 2024 Virbac reported vaccines sales of €214m, ~18% of group revenue. Strong brand loyalty stems from consistent field efficacy and vet preference.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eParasiticides \u0026amp; ectoparasite control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOral, spot-on and collar formulations for fleas, ticks and gastrointestinal worms form a core Virbac revenue stream, anchored in the recurring preventive care market; the global ectoparasiticide market was estimated at about USD 5.8 billion in 2024. Subscription and multi-pack sales drive predictable cash flow and high repeat purchase rates, while bundles with point-of-care diagnostics or automated reminders measurably boost adherence and refill frequency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNutraceuticals \u0026amp; supplements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpnutraceuticals and supplements target otc skin joint general health needs sold via veterinary channels retail capturing higher margins through brand differentiation trust in clinical claims pet supplement market supporting category expansion.\u003e\u003cpcross-selling with therapeutic regimens boosts lifetime value and adherence supplements often carrying gross margins materially above pharmaceuticals strengthening virbac revenue mix margin profile.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannels: vets + retail\u003c\/li\u003e\n\u003cli\u003eFocus: skin, joint, general health\u003c\/li\u003e\n\u003cli\u003eMarket size: ~USD 2.0bn (2024)\u003c\/li\u003e\n\u003cli\u003eBenefit: higher margins, cross-sell\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pcross-selling\u003e\u003c\/pnutraceuticals\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServices \u0026amp; partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eServices \u0026amp; partnerships combine training, diagnostics alliances and co-development deals to monetize Virbac’s expertise, supporting the group’s ~€1.6bn 2024 revenues; large accounts buy data and bespoke education packages while public health tenders drive recurring contract wins and occasional milestone or licensing income supplements product sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTraining \u0026amp; diagnostics partnerships\u003c\/li\u003e\n\u003cli\u003eCo-development deals\u003c\/li\u003e\n\u003cli\u003eData\/education packages for large accounts\u003c\/li\u003e\n\u003cli\u003eTender-based public health programs\u003c\/li\u003e\n\u003cli\u003eMilestone\/licensing income\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e€1.6bn\u003c\/strong\u003e 2024 pet-health revenue led by \u003cstrong\u003e€214m\u003c\/strong\u003e vaccines, parasiticides, nutraceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVirbac’s revenue mix combines prescription therapeutics, vaccines (€214m in 2024, ~18% of group), recurring parasiticide sales (global market ~USD 5.8bn in 2024) and nutraceuticals (pet supplement market ~USD 2.0bn in 2024), plus services, partnerships and tenders supporting ~€1.6bn group revenue in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccines\u003c\/td\u003e\n\u003ctd\u003e€214m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003e€1.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098480513372,"sku":"virbac-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/virbac-business-model-canvas.png?v=1781809307","url":"https:\/\/pestel-analysis.com\/products\/virbac-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}